Hanmi Pharmaceutical
As of the edition of 20 October 2026, Hanmi Pharmaceutical runs 108 drugs, 6 of them marketed; it is on route A at 3 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 15 |
| Went quiet | 50 |
| Stopped | 4 |
| Status not established | 33 |
| Total | 108 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Esomeprazole | none listed | 2 |
| Ambroxol | none listed | 0 |
| Acetylcarnitine | none listed | 0 |
| Tirbanibulin | Ends 2038 (patent) | 1 |
| Eflapegrastim | Ends 2034 (computed from the first US licence) | 1 |
| Eperisone | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 3 targets, route B at 0 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Hanmi Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 25 trials led
- Heart and blood vessels: 14 trials led
- Hormones: 13 trials led